Short- and long-term T cell and antibody responses following dexamethasone treatment in COVID-19
Rattachement africain : de. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUNDAfter its introduction as standard-of-care for severe COVID-19, dexamethasone has been administered to a large number of patients globally. Detailed knowledge of its impact on the cellular and humoral immune response to SARS-CoV-2 remains scarce.METHODSWe included immunocompetent individuals with (a) mild COVID-19, (b) severe COVID-19 before introduction of dexamethasone treatment, and (c) severe COVID-19 infection treated with dexamethasone from prospective observational cohort studies at Charité-Universitätsmedizin Berlin, Germany. We analyzed SARS-CoV-2 spike-reactive T cells, spike-specific IgG titers, and serum neutralizing activity against B.1.1.7 and B.1.617.2 in samples ranging from 2 weeks to 6 months after infection. We also analyzed BA.2 neutralization in sera after booster immunization.RESULTSPatients with severe COVID-19 and dexamethasone treatment had lower T cell and antibody responses to SARS-CoV-2 compared with patients without dexamethasone treatment in the early phase of disease, which converged in both groups before 6 months after infection and also after immunization. Patients with mild COVID-19 had comparatively lower T cell and antibody responses than patients with severe disease, including a lower response to booster immunization during convalescence.CONCLUSIONDexamethasone treatment was associated with a short-term reduction in T cell and antibody responses in severe COVID-19 when compared with the nontreated group, but this difference evened out 6 months after infection. We confirm higher cellular and humoral immune responses in patients after severe versus mild COVID-19 and the concept of improved hybrid immunity upon immunization.FUNDINGBerlin Institute of Health, German Federal Ministry of Education, and German Federal Institute for Drugs and Medical Devices.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Short- and long-term T cell and antibody responses following dexamethasone treatment in COVID-19
- Date Crossref
- 24/04/2023
- Éditeur
- American Society for Clinical Investigation
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Humboldt-Universität zu Berlin pays non établi dans la noticeUniversité ou école supérieure
-
Charité - Universitätsmedizin Berlin pays non établi dans la noticeÉtablissement de santé
-
University of Cologne Institute of Virology pays non établi dans la noticeUniversité ou école supérieure
-
University Hospital Cologne Institute of Virology pays non établi dans la noticeÉtablissement de santé
-
German Center for Infection Research pays non établi dans la noticeStructure de recherche
-
Universität Hamburg pays non établi dans la noticeUniversité ou école supérieure
-
University Medical Center Hamburg-Eppendorf Department of Tropical Medicine pays non établi dans la noticeÉtablissement de santé
-
Institut für Hygiene und Umwelt pays non établi dans la noticeStructure de recherche
-
Bernhard Nocht Institute for Tropical Medicine pays non établi dans la noticeStructure de recherche
-
Berlin Institute of Health at Charité - Universitätsmedizin Berlin pays non établi dans la noticeStructure de recherche
-
German Center for Lung Research pays non établi dans la noticeStructure de recherche
-
Department of Infectious Diseases pays non établi dans la noticeInstitution
Humboldt-Universität zu Berlin, Charité - Universitätsmedizin Berlin et Institute of Virology — University of Cologne, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.